Kunal Kanitkar, MD
Ophthalmology · Lexington, SCNPI 1639210925
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $66,540 of the $83,322 with a category attached, or 79.9%. Sun Pharmaceutical Industries Inc. accounts for 90.9% of it on its own, with 30 other manufacturers making up the rest. Reporting peaked in 2023 at $24,041 and has fallen 56.5% since, to $10,468 in 2025. Among ophthalmology clinicians in SC with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 434 payments — averaging $191.99 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Sun Pharmaceutical Industries Inc.$76K
- AbbVie$897
- Alcon$771
- Sight Sciences, Inc.$655
- Biotissue Holdings Inc.$541
- Aerie Pharmaceuticals, Inc.$483
- plus $4K from 25 others
What the payments were for
- Speaking & faculty fees$66,54080%
- Travel & lodging$5,5227%
- Food & beverage$11,16713%
- Education$930%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Sun Pharmaceutical Industries Inc. | 173 | $75,756 |
| AbbVie(2 entities) | 30 | $897 |
| Alcon | 22 | $771 |
| Sight Sciences, Inc. | 24 | $655 |
| Biotissue Holdings Inc. | 7 | $541 |
| Aerie Pharmaceuticals, Inc. | 5 | $483 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 28 | $475 |
| NEW World Medical,inc. | 4 | $421 |
| Novartis | 17 | $376 |
| Bausch & Lomb Americas Inc. | 21 | $369 |
| Mallinckrodt Hospital Products Inc. | 11 | $299 |
| Kala Pharmaceuticals, Inc. | 20 | $285 |
| Tarsus Pharmaceuticals, Inc. | 10 | $262 |
| Johnson & Johnson Surgical Vision, Inc. | 3 | $220 |
| Glaukos Corporation | 4 | $214 |
| Dompe US, Inc. | 9 | $193 |
| Oyster Point Pharma, Inc. | 11 | $185 |
| Omeros Corporation | 4 | $162 |
| Amgen(2 entities) | 6 | $151 |
| Rxsight Inc | 3 | $123 |
| Harrow Eye, LLC | 5 | $117 |
| Mallinckrodt Enterprises LLC | 5 | $104 |
| Optos, Inc. | 1 | $53 |
| ANI Pharmaceuticals, Inc. | 1 | $42 |
| Akorn, Inc. | 2 | $42 |
| Shire North American Group Inc | 3 | $38 |
| Hoffmann-la Roche Limited | 1 | $26 |
| Carl Zeiss Meditec USA, Inc. | 1 | $17 |
| Eyevance Pharmaceuticals LLC | 1 | $16 |
| Ocular Therapeutix, Inc. | 1 | $16 |
| Abbott | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- CEQUA$73,252
- Rocklatan$374
- Rhopressa$374
- Clareon$275
- OMNI(R) SURGICAL SYSTEM (US)$264
- Kahook Dual Blade$255
- Clearpath$255
- Ahmed Glaucoma Valve$255
- Streamline$255
- Via360$255
- SION SURGICAL INSTRUMENT$150
- OMIDRIA$125
- VUITY$125
- XEN GLAUCOMA TREATMENT SYSTEM$114
How this compares
$83,322 in reported general payments places this provider in the 95th percentile of 293 ophthalmology providers in South Carolina.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RestasisCyclosporine | 159 | $144,046 |
| LumiganBimatoprost | 218 | $107,640 |
| XiidraLifitegrast | 100 | $84,684 |
| Cyclosporine | 161 | $69,164 |
| TyrvayaVarenicline Tartrate | 36 | $30,132 |
| CequaCyclosporine | 46 | $29,456 |
| RhopressaNetarsudil Mesylate | 43 | $21,638 |
| RocklatanNetarsudil Mesylat/Latanoprost | 44 | $19,642 |
| VyzultaLatanoprostene Bunod | 30 | $13,022 |
| Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol | 64 | $12,187 |
| CombiganBrimonidine Tartrate/Timolol | 29 | $10,468 |
| MieboPerfluorohexyloctane/Pf | 14 | $10,429 |
| Loteprednol Etabonate | 66 | $8,772 |
| Prednisolone Acetate | 221 | $8,638 |
| Travoprost | 29 | $8,186 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieRestasis, Lumigan, Combigan | $897 | $262,155406 claims |
| Bausch & Lomb Americas Inc.Xiidra, Vyzulta, Miebo | $369 | $108,135144 claims |
| Aerie Pharmaceuticals, Inc.Rhopressa, Rocklatan | $483 | $41,27987 claims |
| Oyster Point Pharma, Inc.Tyrvaya | $185 | $30,13236 claims |
| Sun Pharmaceutical Industries Inc.Cequa | $75,756 | $29,45646 claims |
| Bausch & Lomb, A Division Of Bausch Health US, LLCLoteprednol Etabonate, Lotemax Sm, Alrex | $475 | $16,821100 claims |
| AlconSimbrinza | $771 | $6,60021 claims |
| Eyevance Pharmaceuticals LLCTobradex St | $16 | $3,25414 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 293 ophthalmology providers in South Carolina.
Other ophthalmology in Lexington
- John WaltersLexington$6K
- Kerry SolomonMt Pleasant$1.7M
- William ClarkWest Columbia$768K
- George WaringMt Pleasant$645K
- Karolinne RochaCharleston$552K
- Joseph BishopHilton Head Island$136K
- Erik HappMt Pleasant$124K
- Matthew ClaryColumbia$119K
- Carl SloanMyrtle Beach$78K
- David VromanLadson$61K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.